Screening for Prostate Cancer PowerPoint Presentation

Slide 1 -

CARCINOMA DELLA PROSTATA

Slide 2 -

PROSTATE CANCER Prostate Anatomy

Slide 3 -

Prostate cancer is a disease predominantly of the older male population. Autopsy series have indicated that 15% to 30% of men older than the age 50 years have histologic evidence of prostate cancer

Slide 4 -

PROSTATE CANCER DEATHS BY AGE

Slide 5 -

ppt slide no 5 content not found

Slide 6 -

ppt slide no 6 content not found

Slide 7 -

ppt slide no 7 content not found

Slide 8 -

ppt slide no 8 content not found

Slide 9 -

Risk Factors for Prostate Cancer Age – Found mainly in men over age 55. Average age of diagnosis is 70 Family History – Men’s risk is higher if father or brother is diagnosed before the age of 60 Race – Prostate cancer is found more often in African American men then White men. It is less common in Asian and American Indian men Dietary factors – Evidence suggests that a diet high in fat may increase the risk of prostate cancer and diets high in fruits and vegetables decrease the risk

Slide 10 -

Risk for Developing Prostate Cancer

Slide 11 -

Genetic alterations associated with progression of prostate cancer

Slide 12 -

Hypothalamus pituitary testicular axis

Slide 13 -

Detailed schematic: Lateral section of a normal prostate

Slide 14 -

PROSTATE CANCER Stage A : Deep tumor: may not be detected by digital-rectal exam Stage B: Tumor may be detected by DRE or ultrasound Stage C: Spread to surrounding tissue Stage D: Metastasis to bone and lymph nodes

Slide 15 -

ppt slide no 15 content not found

Slide 16 -

The Gleason grading system is used to evaluate or grade prostate cancer cells obtained by needle biopsy. The cells are assigned a number between 1 and 5 nearly normal cells are grade 1, and the most abnormal are grade 5. The scores of the two most common cell patterns are added together. Gleason scores range from 2 to 10. The higher the grade, the more aggressive the cancer. The Gleason scoring system for prostate cancer.

Slide 17 -

ppt slide no 17 content not found

Slide 18 -

Prostatic Intraepithelial Neoplasia 85% carcinomas have associated PIN High grade PIN has 30-50% risk of CA on subsequent biopsies cf 13% in controls PIN does not cause elevated PSA Atypical foci in 3-5% of biopsies, 50% risk of cancer on repeat biopsy

Slide 19 -

Symptoms of Prostate Cancer Frequent urination Inability to urinate Trouble starting and stopping urination Blood in the urine or semen Painful ejaculation Painful or burning urination

Slide 20 -

Screening for Prostate Cancer Prostate-Specific Antigen Blood Test (PSA) – Measures substance made by the prostate gland Digital Rectal Exam (DRE) – Physical exam of the Prostate Gland Transrectal Ultrasound (TRUS) – Uses sound waves to make an image of the prostate on a video screen

Slide 21 -

Screening … For & Against Organ confined prostate cancer is curable Advanced prostate cancer is incurable Screening offers earlier diagnosis Early detection is our only hope for mortality reduction More men die with Prostate cancer than of it PSA test not accurate enough Biopsy and treatment may cause morbidity No trial to show mortality reduction

Slide 22 -

ppt slide no 22 content not found

Slide 23 -

ppt slide no 23 content not found

Slide 24 -

Factors Increasing PSA Cycling Prostate massage Cystoscopy Ejaculation Prostate biopsy Transrectal Ultrasound Prostate disease

Slide 25 -

Percentage risk of CaP

Slide 26 -

Screening - Improving the PSA PSA Velocity > 0.75 ng/ml/yr PSA Density Age adjusted PSA Molecular forms- free / total PSA

Slide 27 -

PSA Isoforms Free and complexed PSA - ACT FREE / TOTAL ratio < 10% suggestive Complex now measurable

Slide 28 -

Digital Rectal Exam for Prostate Tumors

Slide 29 -

Transrectal ultrasound-guided biopsy of the prostate

Slide 30 -

ppt slide no 30 content not found

Slide 31 -

Management Alternatives Expectant -- Watchful Waiting Radical Prostatectomy Radiation Therapy -- EBRT, 3D - CRT, Brachytherapy: HDR, Seed Hormonal -- Mono Rx, MAB Combination

Slide 32 -

Trans-urethral Resection

Slide 33 -

ppt slide no 33 content not found

Slide 34 -

Prostate CancerTreatment Paradigms Clinically Localized Hormone Refractory Local treatment Endocrine Chemotherapy Relapsed and Newly diagnosed M+

Slide 35 -

Prostate Cancer Treatment Background 50% fail after local treatment 10-15% have distant metastasis at presentation Virtually all progress after endocrine treatment Chemotherapy used for symptomatic control No survival advantage in phase-III trials

Slide 36 -

Endocrine control of prostate cancer

Slide 37 -

Strategies for Androgen Deprivation LHRH = Luteinizing hormone-releasing hormone 5  R = 5-alpha reductase. LH = Luteinizing hormone AR = Androgen receptor T = Testosterone DHT = Dihydrotestosterone.

Slide 38 -

Types of Androgen Deprivation

Slide 39 -

Side Effects of Androgen Deprivation

Slide 40 -

Adjuvant trials. SWOG 9921: adjuvant androgen deprivation versus mitoxantrone plus prednisone plus androgen deprivation in selected high-risk prostate cancer patients following radical prostatectomy, phase III. Prior neoadjuvant therapy is permitted if the duration is 4 months or less and if clinical criteria (PSA 15 ng/mL or biopsy GS    7 or PSA   10 ng/mL and GS   6) are satisfied prior to surgery.

Slide 41 -

Adjuvant trials. RTOG 99-02: phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide for localized high-risk prostate cancer.

Slide 42 -

Adjuvant hormonal therapy. Survival improvements were noted only in one trial conducted by the European Organization for Research and Treatment of Cancer with the use of adjuvant hormonal therapy. (Adapted from Bolla et al.)

Slide 43 -

Adjuvant hormones. Adjuvant hormones after radical prostatectomy have demonstrated survival enhancement in patients with pathologically positive lymph nodes. (Adapted from Messing et al.

Slide 44 -

SWOG Intergroup 0162 trial of continuous versus intermittent androgen deprivation

Slide 45 -

Hormone-independent prostate cancer. The development of hormonal escape is depicted. Despite a high initial response rate to androgen deprivation, essentially all men will fail and progress to androgen independence and ultimately hormone refractory status. Treatment for patients with hormone-refractory prostate cancer must be tailored individually, and take into account the need to maintain quality of life in this terminal stage of the disease. Antiandrogen withdrawal, second-line hormonal therapy, palliative supportive care measures including radiation therapy (external or systemic) and pain control, and chemotherapy are all valid options.

Slide 46 -

Mitoxantrone + Steroids Versus Steroids Alone Table of randomized chemotherapy trials in metastatic disease. Although chemotherapy has not demonstrated an impact on survival yet, the use of mitoxantrone and steroids has, however, demonstrated a significant palliative effect in randomized trials

Slide 47 -

SWOG trial of chemotherapy in metastatic disease. SWOG Intergroup 9916 randomized phase III study of docetaxel + estramustine versus mitoxantrone + prednisone in patients with hormone-refractory prostate cancer; 620 patients must be entered to detect a 33% survival difference. Future directions include exploring biologic therapies such as epithelial growth factor receptor inhibitors and antiangiogenesis strategies.

Slide 48 -

Combined Androgen Deprivation Compared with Monotherapy in Advanced Prostate Cancer

Slide 49 -

Docetaxel in HRPC Multiple phase II studies Responses in 45-82% (similar 95% CI duration) Estramustine based RR higher but more toxic Single agent data (weekly and every 3 wks) consistently safe and effective Superior to mitoxantrone + prednisone?

Slide 50 -

TAX327 Study Design Stratification Pain level PPI ≥ 2 or AS ≥ 10 vs. PPI < 2 or AS < 10 KPS ≤ 70 vs. ≥ 80 Docetaxel 75 mg/m2 q3 wks + Prednisone 5 mg bid Mitoxantrone 12 mg/m2 q3 wks + Prednisone 5 mg bid R A N D O M I Z E Docetaxel 30 mg/m2 wkly 5 of 6 wks +Prednisone 5 mg bid Treatment duration in all 3 arms = 30 wks

Slide 51 -

Overall Survival Median survival Hazard (mos) ratio P-value Combined: 18.2 0.83 0.03 D 3 wkly: 18.9 0.76 0.009 D wkly: 17.3 0.91 0.3 Mitoxantrone 16.4 – – Months 0 6 12 18 24 30 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Docetaxel 3 wkly Docetaxel wkly Mitoxantrone Probability of Surviving

Slide 52 -

TAX 327 Docetaxel 3 Weekly Safe Significantly improves: – Survival (18.9 vs 16.5 months) 24% reduction in the risk of death (95% CI 0.62-0.94, p=.009) – PSA decline - 45% vs. 32%, p<.0005 – Pain response - 35% vs. 22%, p=.01 – Quality of life

Slide 53 -

Prostate CancerTreatment Paradigms Clinically Localized Hormone Refractory Local treatment Docetaxel + P q3 wks Improves survival Endocrine Relapsed and Newly diagnosed M+

Slide 54 -

Prostate CancerTreatment Paradigms Clinically Localized Hormone Refractory Local treatment Endocrine Docetaxel Relapsed and Newly diagnosed M+ ? ?

Slide 55 -

Prostate CancerTreatment Paradigms Clinically Localized Hormone Refractory Local treatment Endocrine Mitoxantrone+P for symptoms Relapsed and Newly diagnosed M+ No Survival Benefit

Slide 56 -

ppt slide no 56 content not found

Slide 57 -

ppt slide no 57 content not found

Slide 58 -

ppt slide no 58 content not found

Slide 59 -

ppt slide no 59 content not found

Slide 60 -

ppt slide no 60 content not found

Slide 61 -

ppt slide no 61 content not found

Slide 62 -

ppt slide no 62 content not found